首页> 外文OA文献 >Sequential therapy for helicobacter pylori in elderly patients: Effectiveness, safety and predictors of success
【2h】

Sequential therapy for helicobacter pylori in elderly patients: Effectiveness, safety and predictors of success

机译:老年患者幽门螺杆菌序贯治疗:有效性,安全性和成功的预测指标

摘要

Background: Sequential therapy is one of the most common regimens for H. pylori eradication. The progressive ageing may lead to several problems in the management of H. pylori. Objective: We aimed to assess the effectiveness/safety of sequential therapy in elderly patients and evaluate possible predictive factors of failure. Methods: We retrospecively enrolled 76 patients >65 years old (elderly group) and 69 controls diagnosed of H. pylori by upper endoscopy/histology and a non-invasive test. Patients received 10-day sequential therapy (esomeprazole 40 mg and amoxicillin 1 g for the first 5 days followed by clarithromycin 500 mg plus tinidazole 500 mg, all b.i.d). Comparison between groups was carried out by t-test or 2 test where appropriate. Binomial logistic regression was used to determine factors influencing treatment failure. Results: Eradication was achieved, at Intention-To-Treat analysis, in the 78.9% and 75.4% in the elderly and control group, respectively, and, at Per-Protocol analysis, in the elderly patients in the 81.1% and in controls in the 76.5%, not statistically different. Both groups experienced a similar rate of side effects (27% vs 26.5% p = 1). At univariate analysis, treatment failure in the elderly group positively correlated with female sex (OR=22.5), side effects (OR=5.3), intestinal metaplasia (OR=6.7) and gastric atrophy (OR=6.8), while negatively with antritis (OR=0.15). However, at multivariate analysis, none of the cited variables was found statistically significant. Conclusion: Sequential therapy is safe in old patients and has satisfactory effectiveness, but an "a priori" model predicting the outcome based only on clinical data is not reliable.
机译:背景:序贯疗法是根除幽门螺杆菌的最常见方案之一。进行性衰老可能导致幽门螺杆菌管理中的几个问题。目的:我们旨在评估老年患者序贯治疗的有效性/安全性,并评估失败的可能预测因素。方法:我们回顾性研究了76例> 65岁(老年组)的患者和69例通过上内镜/组织学和无创性检查诊断为幽门螺杆菌的对照。患者接受为期10天的序贯治疗(头5天服用埃索美拉唑40毫克和阿莫西林1克,然后克拉霉素500毫克加替硝唑500毫克,均服从腹泻)。各组之间的比较通过t检验或2检验进行。二项式逻辑回归用于确定影响治疗失败的因素。结果:在意向治疗分析中,老年组和对照组分别达到了78.9%和75.4%,而按方案分析,在老年患者中则达到了81.1%和对照组。 76.5%,无统计学差异。两组的不良反应发生率相似(27%vs 26.5%p = 1)。在单因素分析中,老年组的治疗失败与女性(OR = 22.5),副作用(OR = 5.3),肠化生(OR = 6.7)和胃萎缩(OR = 6.8)呈正相关,而与胃窦炎呈负相关(OR = 6.8)。 OR = 0.15)。但是,在多变量分析中,没有发现引用的变量具有统计学意义。结论:序贯治疗在老年患者中是安全的,并且具有令人满意的疗效,但是仅根据临床数据预测结果的“先验”模型并不可靠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号